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A clinician scientist often wears a variety of different hats, including 
those of researcher, administrator, mentor and teacher. While other 
prestigious awards may specifically honour research achievements, 
a festschrift acknowledges the many other facets of the career of an 
outstanding and influential scientist. Meaning ‘celebratory writing’ in 
German, a festschrift is a unique publication devoted to the lifelong 
accomplishments of an exceptional scholar, and traditionally includes 
a symposium, followed by the publication of a compendium of papers 
contributed by the honoree’s mentees and colleagues.
The notion of a festschrift to celebrate Mike Kew’s career was 
conceived 2 years ago by Chris Kassianides during a visit to Jay 
Hoofnagle at the National Institutes of Health in Bethesda. Jay’s face 
lit up at the suggestion, and that was the signal to steam ahead. The 
concept was enthusiastically endorsed by others, and culminated 
in the Gastroenterology Foundation of South Africa symposium 
in Pretoria in August 2016 at the South African Gastroenterology 
Society congress to commemorate Mike’s achievements and 
ultimately the publication of this festschrift. The symposium was 
dedicated to Mike’s lifelong influence on hepatology, and some of 
his closest collaborators and most prominent colleagues highlighted 
the broad spectrum of his contributions to research on liver disease. 
Perhaps the most inspirational aspect was the admiration and esteem 
the presenters demonstrated in describing his personal attributes. 
Mike brought to academia his insatiable sense of curiosity, his 
passion, his persistence, his determination and his dedication. 
Mike Kew has had one of the most extraordinary careers in South 
African medicine, and is one of the best-known hepatologists of his 
era. The choice of a career that gives one an inner compass of purpose 
invariably has positive effects on one’s life, and Mike is no exception. 
The sheer longevity and productivity of his academic career in 
medicine and hepatology, the magnitude of his impact and the 
quality of his science make Mike Kew the ideal recipient of a living 
celebration of his academic work.
It would be difficult for any prelude to a festschrift in honour of 
Mike Kew to completely cover the many notable achievements of his 
remarkable life and career. Mike had an enviable start to his academic 
career when he graduated cum honoribus primus and top of his class 
at the age of 21 at the University of the Witwatersrand. From that 
auspicious start, he conscientiously followed William Osler’s dictum 
that the magic word for success in medicine is work, sustained hard 
work. Ever the consummate clinical and translational scientist, Mike 
spent over four decades at the forefront of research in hepatology. 
He made substantive contributions, in particular reshaping the 
understanding of hepatocellular carcinoma and hepatitis B virus 
infection in sub-Saharan Africa. Even when retirement beckoned, 
his enthusiasm remained undimmed, and the value of his wisdom 
and experience as a senior scholar was recognised and utilised by the 
Department of Medicine at the University of Cape Town.
One of Mike’s most striking qualities was his skill and talent in 
directing and inspiring his many protégés. Albert Einstein opined 
that ‘you should not use an old map to explore a new world’ and 
this maxim underpinned his career. A good test of mentorship is 
the ability to inspire others, and the recognition that together, the 
landscape can be changed, and new knowledge brought into the 
world. He had an unparalleled intuition in recognising natural 
talent, which resulted in his recruiting and nurturing some of the 
best hepatologists in South Africa in the Department of Medicine 
at the University of the Witwatersrand, ensuring that each protégé 
followed a unique career pathway and that all became expert 
hepatologists. 
There are a plethora of plaudits that describe Mike and the 
trajectory of his journey in South African medicine. During his 
career, he was the recipient of numerous national and international 
awards and honours, which are detailed in subsequent tributes. 
His contributions have left an enduring and indelible legacy. This 
festschrift acknowledges Mike’s impact on hepatology, medicine 
and academia, and the profound influence he had on colleagues and 
coworkers. Few can equal the extent and depth of his accomplishments.
J E J Krige, S R Thomson, E Jonas, C  Kassianides 
Introduction
A favourite Kewism; 'Write in haste and revise at leisure. Good writing is a 
craft, not an art.'
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Michael Charles Kew was born in 1939 in Johannesburg, South Africa. 
His parents, Max and Dorothy Kew, were South African citizens, his 
father a businessman. At an early age, Michael was recognised as a 
brilliant student. He graduated with first class honours from Jeppe 
High School at 15 years of age in 1955. From there, he enrolled at the 
University of the Witwatersrand (Wits) in 1956, the beginning of a 
more than 50-year career in association with the university. He received 
his MB BCh in 1961 (graduating cum honoribus primus), followed by 
an FCP (SA) in 1965, a medical doctorate (MD) in 1968, a PhD in 
1974 and Doctor of Science (DSc) in 1982. His success in academic 
medicine was recognised with his induction as a member of the Royal 
College of Physicians of London (MRCP) in 1971, followed by his 
election as a fellow of the Royal College (FRCP) in 1979. This rapid 
acquisition of professional degrees and recognition is a testament to 
his academic and research performance at the Johannesburg Teaching 
Hospital Complex and University of the Witwatersrand. Here he began 
work as a physician in the Department of Medicine in 1967, later 
becoming a principal physician and senior lecturer (1971), a consultant 
hepatologist (1972), professor of medicine (1978) and senior physician 
and physician in charge of the Liver Unit (1972), as well as a member 
of the SA Medical Research Council (1997). 
Professor Kew’s initial academic and research studies were 
on a broad spectrum of liver diseases including viral hepatitis, 
drug-induced liver disease, portal hypertension, haemosiderosis, 
heatstroke and hepatocellular carcinoma (HCC). These were the 
clinical conditions and challenges that he faced on the wards of the 
Johannesburg Teaching Hospital, and particularly at Baragwanath 
Hospital that serves the sprawling Soweto township. A very special 
and dramatic challenge was HCC, which in Johannesburg, unlike 
other places in the world, was an extremely aggressive, rapidly fatal 
cancer affecting young adults in their 20s and 30s, rather than the 
middle-aged or elderly, as seen in the rest of the world. 
In 1970, Dr Kew was awarded a Wellcome Research Fellowship to 
work in the Liver Unit at the Royal Free Hospital, London, with the 
world-renowned Dame Sheila Sherlock. There he pursued investigational 
studies on portal hypertension, but also carried out a clinical study on 
the spectrum of HCC, co-authoring with Dame Sheila what is now 
recognised as a classic clinical description of this little-understood cancer. 
Returning to South Africa, Dr Kew began what became a life-
long commitment to the study of HCC. His initial studies were 
largely descriptive and clinical, but he rapidly initiated analyses of 
pathogenesis based upon epidemiology and application of the serology, 
virology and molecular assays for the newly discovered hepatitis 
B virus (HBV). He and others showed that chronic infection with 
HBV was closely linked to liver cancer, and probably nowhere more 
strikingly than in sub-Saharan Africa. In a series of epidemiological, 
clinical, histological, virological and molecular studies, Professor Kew 
mapped out the close association of HCC with chronic HBV infection, 
the integration of HBV DNA into the tumour cells, the contributing 
factors of age, sex, iron status and environmental factors in the 
progression and expression of HCC, thereby establishing himself as the 
foremost authority on this significant tumour.
I first met Professor Kew in 1978, at the 2nd International 
Symposium on Viral Hepatitis, held in San Francisco. I had just 
finished training in gastroenterology-hepatology with Leonard Seeff 
(another South African) at the Washington DC VA Hospital, and 
started in the Liver Diseases Section of the National Institutes of 
Health. Mike gave the plenary overview presentation on hepatitis B 
and liver cancer. The talk was clear, concise and convincing, and given 
in that crisp, distinctive South African accent. It was immediately 
apparent to me and to all in the audience that this was someone who 
knew what he was talking about, a speaker who had seen and taken 
care of patients with liver cancer. It was immediately evident that he 
was a scholar, a careful thinker and, importantly, a clinical and basic 
scientist. Until that time, epidemiologists, pathologists, cell biologists 
and clinicians were the experts on HCC. Michael was all of these. He 
brought a freshness and excitement to the topic, proving a thoughtful 
and complete approach to understanding liver cancer and the role of 
hepatitis viruses, viral genes, host genes and environmental factors in 
its aetiology and pathogenesis. He also provided insights into what 
might ultimately be done for the prevention, early detection and 
treatment of HCC. 
Following the meeting in 1978, Michael Kew was an invariable 
presence as a speaker at international symposia on viral hepatitis. 
In addition to contributing data from South Africa and the African 
continent, he succeeded in providing an overview and a balanced 
understanding of HCC, the most dreaded complication of viral 
hepatitis. He contributed to our knowledge of hepatitis B and 
liver cancer, documenting the abysmal results of conventional 
chemotherapy, and initiated trials of new therapies for chronic HBV 
infection, while documenting the changing epidemiology of hepatitis 
B and liver cancer.
Professor Kew was awarded a Fogarty Visiting Scientist position 
with Dr Robert Purcell in the Hepatitis Viruses section of the 
National Institutes of Health (NIH), and there he developed a 
working knowledge of the laboratory tools required to advance his 
research into the molecular virology of hepatitis B and liver cancer. I 
was at the NIH at the time, and asked Bob Purcell why we didn’t see 
more of Mike Kew. Purcell answered that he was too busy, and added 
that Mike was the hardest-working, most dedicated Fogarty scholar 
who he had ever worked with. Following the 2-year sabbatical, 
Michael returned to Johannesburg, where he continued to make 
important contributions to our understanding of hepatitis B and 
HCC, using molecular tools to further elucidate the interaction of 
hepatitis B with the liver. He further explored co-factors that might 
alter viral carcinogenesis, defining the roles of genotypes and viral 
variants, the role of co-infection with hepatitis C and D viruses and 
viral host interactions. He also explored the potential role of chronic 
hepatitis B therapy as a means of decreasing the risk of HCC, and the 
changing epidemiology of hepatitis B and HCC in South Africa and 
worldwide. 
I have personally benefitted greatly from my association with 
Professor Kew, and must pay tribute to his important role as a mentor 
of young physicians, attracting the best and brightest into the field of 
hepatology and viral hepatitis research. At the Liver Diseases Section 
of the NIH in the 1980s and 90s, Michael sent us three of his best 
trainees. All three were stars. 
Geoff Dusheiko was the first hepatology fellow trained by Mike 
Kew. He came to our group a year after I joined the NIH. He got us 
started in hepatitis B immunology, and set up assays for HBV DNA 
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polymerase that were the bedrock of much that we did clinically on 
hepatitis B in ensuing years. Geoff returned to South Africa, where he 
worked with Michael Kew starting trials for the therapy of hepatitis 
B in South Africa, and 5 years later moved to London to become 
Professor of Medicine and chief of the Hepatology Section at the 
Royal Free Hospital.
Adrian di Bisceglie was our second Kew trainee. Adrian quickly 
showed his expertise, sound judgment and maturity, and was 
appointed a senior staff physician within 2 years of arriving, and 
subsequently was made chief of the Hepatitis Section. In the lab, he 
developed assays for HBV DNA in serum and liver, and helped us 
embark on studies for the therapy of chronic hepatitis B and what was 
then known as ‘non-A, non-B’ hepatitis using recombinant human 
interferon alpha. Adrian later went on to become Chief of Hepatology 
and Chairman of Medicine at St Louis University, and president of 
the American Association for the Study of Liver Diseases (AASLD). 
The third Kew trainee was Chris Kassianides, who developed the 
duck HBV model in our lab and participated in our early trials of 
therapy for hepatitis B, C and D. Chris became a close friend, and a 
frequent visitor even after he left to finish specialty gastroenterology 
training and later returned to South Africa. Chris has become a 
champion for advanced hepatology and gastroenterology training 
in South Africa and the African subcontinent and is founder and 
chairman of the Gastroenterology Foundation of South Africa. 
Chris conceptualised and organised a truly magnificent festschrift 
symposium in 2016 to honour Michael Kew, which led to the 
compilation of this festschrift.
I write of many things that occurred 20, 30 and even 40 years ago. 
I have achieved the age where I realise that one’s contribution to 
biomedical science is not only in the number of papers you publish, 
or how often you are invited to speak, or what honorary degrees and 
awards you can claim. Perhaps more importantly, one’s contribution 
is also measured in what you leave behind, those you have mentored, 
your trainees, your scientific children in whom you foster a love and 
commitment of science and medicine, and who then pass on this 
enthusiasm and commitment to future generations. Professor Kew 
has been successful in all of these respects, and a leading source in the 
growing light that has surrounded the darkness of viral hepatitis and 
the disease burden that it causes. I am proud to have been asked to 
contribute to this festschrift for this most deserving physician, scholar, 
researcher, teacher and mentor. Mike, congratulations on a sterling and 
successful career.
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Professor Mike Kew and the Royal Free Hospital
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The Royal Free Hospital in London is one of the world’s foremost 
landmarks in hepatology, being the hospital where Professor Dame 
Sheila Sherlock worked, providing key contributions to the discipline. 
Sheila Sherlock’s legacy is a most impressive establishment, with 
possibly hundreds of clinical and research fellows having received 
training and inspiration from her, and subsequently from her closest 
disciples after her death in 2002. Many of these young trainees came 
to London from different parts of the world, and went back to their 
countries fundamentally primed to become leading hepatologists. 
The original Royal Free Hospital was located in the centre of 
London, in Gray’s Inn Road, and was then moved to the new 
establishment in Hampstead, North London, in 1974. 
Professor Mike Kew joined the group led by Sheila Sherlock in 
1969, and spent 1 year as specialist registrar at the Royal Free in 
Gray’s Inn Road. London was probably the most exciting city in the 
world at the time. Everything seemed to happen there, with new 
trends originating from what was defined as ‘swinging London’. In 
the imagination of somebody from South Africa, London was still 
the capital of the great British Empire, when in reality, the empire was 
over, and London was pursuing a different and far brighter future. 
However, the old Royal Free in Gray’s Inn Road was an outdated 
structure, totally insufficient to satisfy the blossoming rapid expansion 
of the more and more specialised branches of medicine. The building 
was like an old veteran of many battles, full of glory and medals, 
but close to ruin. Hepatology, one of the newcomers in the race to 
medical specialisation, was mostly relegated to an interconnected 
series of huts on the roof of the old hospital building (Fig. 1). I can 
imagine young Dr Kew, used to the warmth, spaces and colours of 
Africa, encountering the grey and humid London atmosphere, and 
moving from one hut to another between ward rounds and academic 
meetings. 
In the memory of the few people I was able to contact and ask 
about the days of Mike Kew in London, and most notably one of my 
predecessors, Professor Neil MacIntyre, Mike was regarded as a shy 
but extremely knowledgeable doctor, and, apparently, a formidable 
tennis player. This may have contributed to his making a favourable 
impression on Dame Sheila, who loved tennis and did not allow 
anybody to beat her. In this regard, it would be interesting to know 
Mike’s point of view!
The intense activity of Mike Kew at the Royal Free was largely 
concentrated on renal impairment in patients with cirrhosis of 
the liver. In 1971, Mike published his first landmark paper on this 
topic in The Lancet.[1] By employing the innovative 133Xe washout 
technique, Mike and colleagues clearly demonstrated for the first 
time that a decrease in creatinine clearance is invariably associated 
with significant cortical hypoperfusion, likely attributable to active 
vasoconstriction of the cortical vessels. In a paper published in 
1972,[2] Mike and coworkers showed that an identical situation occurs 
in non-cirrhotic portal hypertension, and established the concept 
that vasoconstriction of the renal cortex occurs as a consequence 
of portal hypertension independently of the progressive failure of 
liver function typical of advanced cirrhosis. Working along these 
lines, these authors provided the first characterisation of portal 
hypertension in primary biliary cirrhosis.[3] Another key intuition in 
this pioneering area of hepatology was the relationship between the 
circulatory derangement typical of decompensated cirrhosis and renal 
function.[4] In this paper, the authors showed that the administration 
of octapressin, a vasopressin analogue, was able to improve renal 
function only in those patients in whom the drug increased a very 
low mean arterial pressure, thus establishing the relationship between 
effective blood volume and glomerular filtration rate in cirrhosis. 
Taken together, these acquisitions represent the very fundamental 
basis of our current understanding of renal function in cirrhosis, 
the hepatorenal syndrome and the relative therapeutic approaches. 
I vividly remember quoting Mike Kew’s paper in my MD thesis, and 
I was deeply honoured to meet him for the first time in Cape Town.
This intense and innovative research activity had distracted Mike 
Kew from his original and everlasting love: hepatocellular carcinoma 
(HCC). Indeed, he published only one paper on this topic with Sheila 
Sherlock, dedicated to the diagnosis of this malignancy.[5] I can 
imagine that Mike was probably the hepatologist with the greatest 
experience in HCC at the Royal Free, as a result of the far higher 
incidence of this cancer in Africa, and the still poor recognition of 
the association between chronic liver disease and HCC in Europe 
and the USA.
I feel honoured to celebrate in this article the association between the 
Royal Free Hospital and one of its most renowned fellows in hepatology. 
Mike’s lifetime achievements are a great source of motivation for me 
and for the young research fellows that I am honoured to mentor and 
host, thus maintaining Sheila Sherlock’s legacy.
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Fig. 1. The huts on the roof at the old Royal Free Hospital in Gray’s Inn Road, 
London.
